<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydrocortisone (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydrocortisone (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hydrocortisone (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9144" href="/d/html/9144.html" rel="external">see "Hydrocortisone (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="11696" href="/d/html/11696.html" rel="external">see "Hydrocortisone (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8116174"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Alkindi Sprinkle;</li>
<li>Cortef;</li>
<li>Solu-CORTEF</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869190"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AURO-Hydrocortisone;</li>
<li>Cortef;</li>
<li>Solu-CORTEF</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10820821"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenal Corticosteroid</span>;</li>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Antiasthmatic</span>;</li>
<li>
<span class="list-set-name">Corticosteroid, Systemic</span>;</li>
<li>
<span class="list-set-name">Glucocorticoid</span></li></ul></div>
<div class="block don drugH1Div" id="F53462658"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21483d16-7696-4697-a3b1-8aeb6dd6a43a">Bronchopulmonary dysplasia/Chronic lung disease, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchopulmonary dysplasia (BPD)/Chronic lung disease, prophylaxis:</b> Limited data available: <b>Note:</b> AAP does not recommend routine use of postnatal corticosteroids; decision to use should be individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cummings.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cummings.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates: GA &lt;28 weeks and PNA ≤48 hours: IV: 1 mg/kg/day divided every 12 hours for 7 days followed by 0.5 mg/kg/day once daily for 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26916176','lexi-content-ref-28384828','lexi-content-ref-29321180','lexi-content-ref-15574629','lexi-content-ref-10585975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26916176','lexi-content-ref-28384828','lexi-content-ref-29321180','lexi-content-ref-15574629','lexi-content-ref-10585975'])">Ref</a></span>); low-dose early hydrocortisone was shown to improve survival without BPD in neonates born at GA &lt;28 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26916176','lexi-content-ref-28384828','lexi-content-ref-29321180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26916176','lexi-content-ref-28384828','lexi-content-ref-29321180'])">Ref</a></span>). Several studies have shown hydrocortisone to be especially beneficial to neonates weighing &lt;1 kg exposed to chorioamnionitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cummings.2022','lexi-content-ref-31043325','lexi-content-ref-15574629','lexi-content-ref-10585975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cummings.2022','lexi-content-ref-31043325','lexi-content-ref-15574629','lexi-content-ref-10585975'])">Ref</a></span>). Concurrent use with indomethacin is not recommended, as it has been associated with a higher incidence of GI perforation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cummings.2022','lexi-content-ref-15870666','lexi-content-ref-15574629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cummings.2022','lexi-content-ref-15870666','lexi-content-ref-15574629'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a321863-0d22-43c1-89eb-edfd77bc2d8b">Bronchopulmonary dysplasia/Chronic lung disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchopulmonary dysplasia (BPD)/Chronic lung disease, treatment:</b> Limited data available. <b>Note:</b> AAP does not recommend routine use of postnatal corticosteroids; decision to use should be individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cummings.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cummings.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm neonates: GA &lt;30 weeks and PNA 7 to 14 days: IV: 5 mg/kg/day divided every 6 hours for 7 days, followed by 3.75 mg/kg/day divided every 8 hours for 5 days, followed by 2.5 mg/kg/day divided every 12 hours for 5 days, followed by 1.25 mg/kg/dose every 24 hours for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34313697','lexi-content-ref-30694322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34313697','lexi-content-ref-30694322'])">Ref</a></span>). Lower cumulative doses initiated at PNA 14 to 28 days have been studied, but have not shown to have improved survival without moderate or severe BPD or neurodevelopmental impairment at 2 years corrected age or alter the severity of BPD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35320643']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35320643'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afa687ed-131c-4dd7-b289-81195205fdfc">Congenital adrenal hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital adrenal hyperplasia (CAH):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Individualize dose based on growth, hormone levels, and bone age; mineralocorticoid (eg, fludrocortisone) and sodium supplement may be required in salt losers. Guidelines recommend against using commercially-available oral suspension in growing individuals; however, that recommendation is based on data for a commercial suspension that is no longer available. Extemporaneously prepared hydrocortisone suspension has been shown to provide similar cortisol exposure to tablets in pediatric patients with CAH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11099616','lexi-content-ref-30272171','lexi-content-ref-25385533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11099616','lexi-content-ref-30272171','lexi-content-ref-25385533'])">Ref</a></span>). Use caution when changing between dosage forms (eg, from compounded solution or crushed tablet to sprinkles) and monitor closely for potential differences in exposure; dosage adjustment may be necessary. When using the oral sprinkles (Alkindi), round dose to nearest 0.5 or 1 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Oral: Initial: 10 to 15 mg/m<sup>2</sup>/day in 3 divided doses; higher initial doses (20 mg/m<sup>2</sup>/day) may be required to achieve initial target hormone serum concentrations. Administer morning dose as early as possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11099616','lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11099616','lexi-content-ref-30272171'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3423c79c-5626-4067-bcde-ee33608b3fe9">Hypotension, refractory; shock</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension, refractory; shock:</b> Limited data available; various regimens have been reported; optimal dose not established; use the lowest effective dose; higher doses have not been shown to increase efficacy and lead to more adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19693023','lexi-content-ref-28518133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19693023','lexi-content-ref-28518133'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: IV: 0.5 mg/kg/dose every 6 to 12 hours <b>or</b> 1 mg/kg/dose every 8 to 12 hours; duration variable but commonly reported for 1 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16452355','lexi-content-ref-17015536','lexi-content-ref-28518133','lexi-content-ref-11331688','lexi-content-ref-27156187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16452355','lexi-content-ref-17015536','lexi-content-ref-28518133','lexi-content-ref-11331688','lexi-content-ref-27156187'])">Ref</a></span>). Some experts recommend a 1 mg/kg test dose; if no response in 2 to 4 hours, then no further doses are given; if patient does respond, then test dose should be followed by 0.5 mg/kg/dose every 12 hours for GA &lt;34 weeks or 0.5 mg/kg/dose every 6 to 8 hours for GA ≥34 weeks; the dose may be increased to 1 mg/kg/dose if necessary, with the interval guided by patient response. Taper hydrocortisone off as condition allows (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27156187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27156187'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F8116312"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Adjust dose depending upon condition being treated and response of patient. The lowest possible dose should be used to control the condition; when dose reduction is possible, the dose should be reduced gradually. In life-threatening situations, parenteral doses larger than the oral dose may be needed.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="210d52c0-d98e-42be-91ad-4f89035fb409">Adrenal insufficiency, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency, acute (adrenal crisis):</b> Dosage regimens variable; some experts recommend using weight-directed dosing for first dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed:</i> Limited data available: Infants, Children, and Adolescents: IM, IV (preferred), Intraosseous: Initial: 2 to 3 mg/kg once; maximum dose: 100 mg/dose; then for infants: 1 to 5 mg/kg/dose every 6 hours; for children and adolescents, see BSA- or age-directed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18245435','lexi-content-ref-31871244','lexi-content-ref-Cameron.1','lexi-content-ref-Marx.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18245435','lexi-content-ref-31871244','lexi-content-ref-Cameron.1','lexi-content-ref-Marx.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BSA-directed dosing:</i> Limited data available: Infants, Children, and Adolescents: IM, IV (preferred), Intraosseous: Initial: 50 to 100 mg/m<sup>2</sup> once followed by 50 to 100 mg/m<sup>2</sup>/day in 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21867553','lexi-content-ref-25733761','lexi-content-ref-18245435','lexi-content-ref-17242136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21867553','lexi-content-ref-25733761','lexi-content-ref-18245435','lexi-content-ref-17242136'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Age-directed dosing (fixed dosing):</i> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Cameron.1','lexi-content-ref-25561746','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Cameron.1','lexi-content-ref-25561746','lexi-content-ref-Kliegman.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IM, IV (preferred), Intraosseous: 10 to 25 mg once followed by 10 to 25 mg/day in divided doses every 6 hours for 24 hours then subsequent dose reductions and rate determined by patient response.</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;5 years (eg, young children): IM, IV (preferred), Intraosseous: 25 to 50 mg once followed by 25 to 50 mg/day in divided doses every 6 hours for 24 hours then subsequent dose reductions and rate determined by patient response.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥5 years (eg, older children): IM, IV (preferred), Intraosseous: 50 to 100 mg once followed by 50 mg/day in divided doses every 6 hours for 24 hours then subsequent dose reductions and rate determined by patient response.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IM, IV (preferred), Intraosseous: 100 mg once followed by 100 mg/day in divided doses every 6 hours for 24 hours then subsequent dose reduction and rate determined by patient response.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a6608b3-fd67-4c09-a374-bc417c0679c2">Anti-inflammatory or immunosuppressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory or immunosuppressive:</b>
<b>Note:</b> Dosing range variable; individualize dose for disease state and patient response.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 2.5 to 10 mg/kg/day or 75 to 300 mg/m<sup>2</sup>/day divided every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IM, IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Manufacturer's labeling: Initial: 0.56 to 8 mg/kg/day or 20 to 240 mg/m<sup>2</sup>/day in 3 or 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Alternate dosing: Limited data available: 1 to 5 mg/kg/day or 30 to 150 mg/m<sup>2</sup>/day divided every 12 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral, IM, IV, SubQ: 15 to 240 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="83090ab0-5cae-4baa-83a1-108f7171e69a">Congenital adrenal hyperplasia; chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital adrenal hyperplasia (CAH); chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer morning dose as early as possible. Individualize dose by monitoring growth, hormone levels, and bone age; mineralocorticoid (eg, fludrocortisone) and sodium supplement may be required in salt losers. Guidelines recommend against using commercially-available oral suspension in growing individuals; however, that recommendation is based on data for a commercial suspension that is no longer available. Extemporaneously prepared hydrocortisone suspension has been shown to provide similar cortisol exposure to tablets in pediatric patients with CAH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11099616','lexi-content-ref-AAP.1','lexi-content-ref-30272171','lexi-content-ref-25385533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11099616','lexi-content-ref-AAP.1','lexi-content-ref-30272171','lexi-content-ref-25385533'])">Ref</a></span>). Use caution when changing between dosage forms (eg, from compounded solution or crushed tablet to sprinkles) and monitor closely for potential differences in exposure; dosage adjustment may be necessary. When using the oral sprinkles (Alkindi), round dose to nearest 0.5 or 1 mg; when using regular oral tablets, the smallest available dose is 2.5 mg (<sup>1</sup>/<sub>2</sub> of 5 mg tablet). See "Stress dosing; supplemental" for management of patients with CAH during times of physiological stress.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>BSA-directed dosing</i>: Oral (tablets, sprinkles): Initial: 8 to 15 mg/m<sup>2</sup>/day in 3 divided doses; usual range: 10 to 15 mg/m<sup>2</sup>/day; higher initial doses (20 mg/m<sup>2</sup>/day) may be required to achieve initial target hormone serum concentrations; older patients may be able to transition to twice-daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-25561746','lexi-content-ref-30272171','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-25561746','lexi-content-ref-30272171','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Fixed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11099616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11099616'])">Ref</a></span>): Oral (tablets): Usual requirement:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants: 2.5 to 5 mg/<b>dose</b> 3 times/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Children: 5 to 10 mg/<b>dose</b> 3 times/day.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents (fully grown): 15 to 25 mg/day divided in 2 to 3 daily doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3570d6ef-f7f5-425c-9464-7d0146fea1c1">Physiologic replacement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Physiologic replacement:</b> Infants and Children: Oral: 8 to 10 mg/m<sup>2</sup>/day divided every 8 hours; up to 12 mg/m<sup>2</sup>/day in some patients; to replicate diurnal variation, the highest doses are typically administered in the morning and midday dose with the lower dose in the evening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21867553','lexi-content-ref-25561746','lexi-content-ref-19023528','lexi-content-ref-17576782','lexi-content-ref-17242136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21867553','lexi-content-ref-25561746','lexi-content-ref-19023528','lexi-content-ref-17576782','lexi-content-ref-17242136'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ff08ea6-28cb-4b9d-82f2-0fd5561eb4a9">Stress dosing; supplemental</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress dosing; supplemental:</b> Limited data available; dosage regimens variable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing based on the level of physiological stress related to condition; dose should be individualized based on patient and continued until resolution of stressful condition (usually 24 to 48 hours). Typically, supplementation for emotional or minimal physiological stress conditions or prior to exercise is not necessary. Dosing is generally 2 to 3 times physiologic replacement level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25561746','lexi-content-ref-30272171','lexi-content-ref-17242136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25561746','lexi-content-ref-30272171','lexi-content-ref-17242136'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>BSA-directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21867553','lexi-content-ref-17242136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21867553','lexi-content-ref-17242136'])">Ref</a></span>): Oral, IM, IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Mild to moderate stress: 20 to 50 mg/m<sup>2</sup>/day divided into 3 or 4 doses; doses on the lower end of the range (20 to 30 mg/m<sup>2</sup>/day) may be divided twice daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Major stress or surgery: 100 mg/m<sup>2</sup>/day in divided doses every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Planned surgery: Pre-anesthesia of 50 mg/m<sup>2</sup> IV or IM administered 30 to 60 minutes prior to surgery followed by second dose of 50 mg/m<sup>2</sup> as a continuous IV infusion or in divided doses every 6 hours for at least 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Age-directed for moderate stress in patients with congenital adrenal hyperplasia</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30272171'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and preschool children: IV: Initial dose: 25 mg once, followed by a daily dose that is 3 to 4 times the patient's standard maintenance dose in divided doses every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">School-age children: IV: Initial dose: 50 mg once, followed by a daily dose that is 3 to 4 times the patient's standard maintenance dose in divided doses every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: IV: Initial dose: 100 mg once, followed by a daily dose that is 3 to 4 times the patient's standard maintenance dose in divided doses every 6 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9fbc9de2-c68c-430f-a9a4-c98f5c7c643a">Septic shock, fluid and catecholamine-refractory with suspected/proven adrenal insufficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic shock, fluid and catecholamine-refractory with suspected/proven adrenal insufficiency:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BSA-directed dosing</i>
<i>: </i>Infants, Children, and Adolescents: IV: 50 to 100 mg/m<sup>2</sup>/day. <b>Note:</b> The maximum adult daily dose is 200 mg/<b>day</b> (~100 mg/m<sup>2</sup>/<b>day</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28509730','lexi-content-ref-Marx.1','lexi-content-ref-23353941','lexi-content-ref-17242136']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28509730','lexi-content-ref-Marx.1','lexi-content-ref-23353941','lexi-content-ref-17242136'])">Ref</a></span>). In some cases, doses may be titrated up to 50 mg/<b>kg</b>/day as a continuous IV infusion, if necessary, for shock reversal in the short term; however, efficacy data variable with the higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19325359','lexi-content-ref-23353941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19325359','lexi-content-ref-23353941'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-</i>
<i>directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>): <b>Note:</b> Use if BSA not available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV, Intraosseous: 2 mg/kg as a single bolus dose; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Age-</i>
<i>directed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>): <b>Note:</b> Use if BSA and weight are not available:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;3 years: IV, Intraosseous: 25 mg as a single bolus dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥3 to &lt;12 years: IV, Intraosseous: 50 mg as single bolus dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: IV, Intraosseous: 100 mg as a single bolus dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113054"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51113055"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doa drugH1Div" id="F8116314"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9144" href="/d/html/9144.html" rel="external">see "Hydrocortisone (systemic): Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Adjust dose depending upon condition being treated and response of patient. Use the lowest possible dose to control the condition; when dose reduction is possible, reduce the dose gradually. In patients taking chronic oral hydrocortisone who are in life-threatening situations, parenteral doses larger than the oral dose may be needed.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0dbaae28-7737-44c8-a82f-189b6966442e">Adrenal insufficiency, adrenal crisis, treatment and prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency, adrenal crisis, treatment and prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Treatment:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in patients presenting with adrenal crisis, or in patients with myxedema coma whom adrenal crisis has not been ruled out (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266247','lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266247','lexi-content-ref-26760044'])">Ref</a></span>). Appropriate fluid resuscitation is also required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044','lexi-content-ref-Gardner.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044','lexi-content-ref-Gardner.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 100 mg IV bolus given immediately, followed by 25 to 75 mg IV every 6 hours or 200 mg/24 hours as a continuous IV infusion for the first 24 hours. Reassess patient after the initial 24 hours; if clinical status has improved may begin gradually tapering the dose. Once patient is stable, may resume chronic maintenance oral dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-26760044','lexi-content-ref-30272171','lexi-content-ref-Gardner.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-26760044','lexi-content-ref-30272171','lexi-content-ref-Gardner.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Prevention (ie, stress dosing):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use in patients with known adrenal insufficiency or suspected adrenal insufficiency (eg, Cushingoid appearance, prolonged glucocorticoid therapy ≥5 mg/day of prednisone or equivalent) to prevent development of adrenal crisis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8368224','lexi-content-ref-8161268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8368224','lexi-content-ref-8161268'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Acute physiologic stress/illness:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Febrile illness:</i>
<b>Oral:</b> Double the chronic maintenance dose for fever 38°C (100.4°F) to 39°C (102.2°F) or triple the chronic maintenance oral dose for fever &gt;39°C (102.2°F), then return to baseline dose within 1 to 3 days following recovery of fever (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients unable to tolerate oral medication (eg, due to vomiting or diarrhea):</i>
<b>IM, SUBQ:</b> 100 mg dose given early in course of illness; repeat after 6 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Labor/Delivery: </i>
<b>IM, IV:</b> Dosing is individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32424397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32424397'])">Ref</a></span>). One example regimen includes 100 mg IV loading dose at the onset of active labor (or immediately before anesthesia in patients undergoing caesarean section), followed by 50 to 100 mg every 6 hours (given as IM or IV injections) or 200 mg/day given as a continuous IV infusion until delivery; taper dose over 1 to 2 days after delivery before resuming baseline dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADSHG.2017','lexi-content-ref-26760044','lexi-content-ref-34425558']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADSHG.2017','lexi-content-ref-26760044','lexi-content-ref-34425558'])">Ref</a></span>). Usual dosing range: 50 to 100 mg every 6 to 8 hours <b>or</b> 200 to 300 mg/24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23153216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23153216'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Surgical stress:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Minor surgical stress (eg, hernia repair, procedures with local anesthetic): </i>
<b>IV, Oral:</b> Continue chronic maintenance dose administered orally or IV (no additional supplementation needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11779267','lexi-content-ref-Hamrahian.1','lexi-content-ref-8161268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11779267','lexi-content-ref-Hamrahian.1','lexi-content-ref-8161268'])">Ref</a></span>); may give an additional oral dose (eg, 20 mg) postoperatively if signs or symptoms of adrenal insufficiency are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-24330030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-24330030'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Moderate surgical stress (eg, joint replacement, cholecystectomy): </i>
<b>IV:</b> 50 to 75 mg/day (25 mg every 8 to 12 hours) for 1 to 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11779267','lexi-content-ref-8161268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11779267','lexi-content-ref-8161268'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Major surgical stress (eg, major bowel surgery, cardiothoracic surgery, cesarean delivery): </i>
<b>IV, IM:</b></p>
<p style="text-indent:-2em;margin-left:10em;">100 to 150 mg/day (50 mg every 8 to 12 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11779267','lexi-content-ref-8161268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11779267','lexi-content-ref-8161268'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:10em;">100 mg IV loading dose immediately before anesthesia, followed by 50 to 100 mg every 6 hours (given as IM or IV injection) or 200 mg/day given as a continuous IV infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADSHG.2017','lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADSHG.2017','lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Taper dose and resume oral regimen as clinical status improves (eg, after 1 to 3 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11779267','lexi-content-ref-26760044','lexi-content-ref-8161268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11779267','lexi-content-ref-26760044','lexi-content-ref-8161268'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="887c00ba-1eff-432f-a8c3-5bbbb8805034">Adrenal insufficiency, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency, chronic (eg, primary, secondary, classic congenital adrenal hyperplasia)</b>
<b>: Oral:</b> 15 to 25 mg/day in 2 to 3 divided doses. Administer the largest dose in the morning upon awakening, followed by next dose 2 hours after lunch (2-dose regimen) or next dose at lunch, followed by smallest dose in the afternoon no later than 4 to 6 hours before bedtime (3-dose regimen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044','lexi-content-ref-27736313','lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044','lexi-content-ref-27736313','lexi-content-ref-30272171'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f35feb93-6ec4-4a03-aa25-ba8542ef60c5">Adrenal insufficiency, physiologic replacement following resection of an ACTH-producing tumor or unilateral adrenalectomy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency (temporary), physiologic replacement following resection of an ACTH-producing tumor or unilateral adrenalectomy (off-label dose):</b>
<b>Oral:</b> 10 to 12 mg/m<sup>2</sup>/day in 2 to 3 divided doses, with the first dose taken as soon as possible after waking; continue hydrocortisone until HPA axis recovers, generally 6 to 12 months following resection of ACTH-producing tumors or 18 months following unilateral adrenalectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26222757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26222757'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ddae46c-ba78-45cc-967e-ced2afcf46e9">Adrenal insufficiency associated with immune checkpoint inhibitor therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency associated with immune checkpoint inhibitor therapy: </b>
<b>Note: </b>For oral hydrocortisone, usually <sup>2</sup>/<sub>3</sub> of the dose is administered in the morning and <sup>1</sup>/<sub>3</sub> of the dose is administered in the early afternoon (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 1:</i>
<b>Oral:</b> 15 to 20 mg/day in divided doses; if there are residual symptoms, titrate up to a maximum of 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 2:</i>
<b> Oral: </b>30 to 50 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 or 4:</i>
<b> IV: </b>50 to 100 mg every 6 to 8 hours; taper down to oral maintenance corticosteroids over 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance: Oral: </b>15 to 20 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a6608b3-fd67-4c09-a374-bc417c0679c2">Anti-inflammatory or immunosuppressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory or immunosuppressive (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> Initial: 100 to 500 mg/dose at intervals of 2, 4, or 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 20 to 240 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85b2fb27-1a4a-40d6-b8b5-ab95601995d8">Asthma, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute exacerbation (alternative agent) (off-label dose):</b>
<b>Note:</b> Alternative to other corticosteroids in moderate to severe exacerbations or in patients who do not respond promptly and completely to short-acting beta-agonists; administer within 1 hour of presentation to emergency department (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 200 mg in divided doses for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="894e2a7e-3fff-4cb6-8ddb-f11aa30fb548">COVID-19, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, hospitalized patients (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Hydrocortisone is recommended for treatment of COVID-19 in hospitalized patients requiring supplemental oxygen or ventilatory support when dexamethasone is not available or there are specific indications for hydrocortisone. Dosing is extrapolated from a study that used dexamethasone; the equivalent dose of hydrocortisone (or other glucocorticoid) may be substituted if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b> 50 mg every 8 hours for up to 10 days (or until discharge if sooner) as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NIH.2021','lexi-content-ref-WHO.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ba7034d-d776-4af9-b30c-1effde751246">Hypophysitis associated with immune checkpoint inhibitor therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypophysitis associated with immune checkpoint inhibitor therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Initial:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 1:</i>
<b>Oral:</b> 15 to 20 mg/day in divided doses; if there are residual symptoms, titrate up to a maximum of 30 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 2:</i>
<b> Oral: </b>30 to 50 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 or 4:</i>
<b> IV: </b>50 to 100 mg every 6 to 8 hours; taper down to oral maintenance corticosteroids over 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance: Oral: </b>15 to 20 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>) <b>or</b> 10 to 12 mg/m<sup>2</sup>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34172516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34172516'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56b6caea-ebbf-4c1e-93f2-543c99fc4e9b">Iodinated contrast media allergic-like reaction, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iodinated contrast media allergic-like reaction, prevention: Note:</b> Generally reserved for patients with a prior allergic-like or unknown-type iodinated contrast reaction who will be receiving another iodinated contrast agent. Nonurgent premedication with an oral corticosteroid is generally preferred when contrast administration is scheduled to begin in ≥12 hours; however, IV hydrocortisone may be considered in patients unable to take oral medications. Consider an urgent (accelerated) regimen with an IV corticosteroid for patients requiring contrast in &lt;12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonurgent regimen (alternative agent):</i>
<b>IV:</b> 200 mg administered 13 hours, 7 hours, and 1 hour before contrast medium administration in combination with oral or IV diphenhydramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urgent (accelerated) regimen:</i>
<b>IV: </b>200 mg immediately, then 200 mg every 4 hours until contrast medium administration in combination with oral or IV diphenhydramine. In emergent situations (ie, &lt;4 to 5 hours until contrast is required), may consider hydrocortisone 200 mg in combination with IV diphenhydramine 1 hour prior to contrast (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c9f759a1-600e-4dfb-8205-0b25031e6354">Septic shock, inadequate response to fluid resuscitation and vasopressor therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic shock, inadequate response to fluid resuscitation and vasopressor therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 50 mg bolus every 6 hours <b>or</b> 100 mg every 8 hours for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29490185','lexi-content-ref-9559600','lexi-content-ref-27483065','lexi-content-ref-18184957','lexi-content-ref-34605781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29490185','lexi-content-ref-9559600','lexi-content-ref-27483065','lexi-content-ref-18184957','lexi-content-ref-34605781'])">Ref</a></span>). Consider a taper over several days to avoid possible hemodynamic deterioration, which may occur with abrupt withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29490185','lexi-content-ref-27483065','lexi-content-ref-12426230','lexi-content-ref-18184957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29490185','lexi-content-ref-27483065','lexi-content-ref-12426230','lexi-content-ref-18184957'])">Ref</a></span>). Infrequently used in combination with fludrocortisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12186604','lexi-content-ref-29490185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12186604','lexi-content-ref-29490185'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f1475225-321a-4979-8339-62b5dcdf93d0">Thyroid storm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid storm (off-label use):</b>
<b>IV:</b> 300 mg loading dose, followed by 100 mg every 8 hours; use in combination with other appropriate agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>). The optimal duration of therapy is unknown; taper and discontinue therapy as clinical status improves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23148158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23148158'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98315b15-0fa6-413b-8816-a7524ae8139c">Ulcerative colitis, acute, remission induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, acute (severe), remission induction (off-</b>
<b>label dose):</b>
<b>IV:</b> 100 mg every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605'])">Ref</a></span>). Some experts recommend not exceeding 300 mg/day to decrease the risk of colectomy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31945371']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31945371'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990334"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The pharmacokinetics and pharmacodynamics of hydrocortisone in kidney impairment are not well understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15634032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15634032'])">Ref</a></span>). Cortisone metabolism and excretion may be impaired with kidney dysfunction (cortisone in its free form and its breakdown products are excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11967038','lexi-content-ref-17437510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11967038','lexi-content-ref-17437510'])">Ref</a></span>). The clinical implications of these pharmacokinetic alterations are unclear.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987687"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F8116246"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Bradycardia, cardiac arrhythmia, cardiac failure (especially in susceptible patients), cardiomegaly, circulatory shock, embolism (fat), hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (post-myocardial infarction), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Acne vulgaris, allergic dermatitis, atrophic striae, burning sensation of skin (especially in the perineal area after IV injection), diaphoresis, ecchymoses, erythema of skin, facial erythema, hyperpigmentation, hypertrichosis, hypopigmentation, inadvertent suppression of skin test reaction, skin rash, thinning hair, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (secondary unresponsiveness, particularly during trauma, surgery, or illness), Cushing syndrome, decreased serum potassium, drug-induced Cushing’s syndrome, fluid retention, glycosuria, growth retardation, hirsutism, HPA-axis suppression, hyperglycemia (including increased requirements for insulin or oral hypoglycemic agents in diabetes mellitus), hypokalemic alkalosis, impaired glucose tolerance/prediabetes, lipodystrophy, manifestation of prediabetes, menstrual disease, moon face, negative nitrogen balance (due to protein catabolism), pituitary insufficiency (secondary unresponsiveness, particularly during trauma, surgery, or illness), protein catabolism, sodium retention, weight gain</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal distention, gastrointestinal perforation (small and large intestine, particularly in patients with inflammatory bowel disease), hiccups, impaired intestinal carbohydrate absorption, increased appetite, nausea, pancreatitis, peptic ulcer (with possible perforation and hemorrhage), ulcerative esophagitis</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Asthenospermia, oligospermia</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Leukocytosis, petechia</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Hepatomegaly, increased liver enzymes (usually reversible on discontinuation)</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Infection: Increased susceptibility to infection, sterile abscess</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Atrophy at injection site (cutaneous and subcutaneous), post-injection flare (intra-articular use), skin edema</p>
<p style="text-indent:-2em;margin-left:2em;">Nervous system: Depression, emotional lability, euphoria, headache, increased intracranial pressure (with pseudotumor cerebri; usually following discontinuation), insomnia, malaise, myasthenia, neuritis, neuropathy, paresthesia, personality changes, psychic disorder, seizure, tingling of skin (especially in the perineal area after IV injection), vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Amyotrophy, aseptic necrosis of femoral head, aseptic necrosis of humeral head, Charcot arthropathy, osteoporosis, pathological fracture (long bones), rupture of tendon (particularly rupture of Achilles tendon), steroid myopathy, vertebral compression fracture</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blindness (rare, periocular injection), exophthalmos, glaucoma, increased intraocular pressure, retinopathy (central serous chorioretinopathy), subcapsular posterior cataract</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Wound healing impairment</p></div>
<div class="block coi drugH1Div" id="F8116223"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to hydrocortisone or any component of the formulation; systemic fungal infections; use in premature infants (formulations containing benzyl alcohol only); idiopathic thrombocytopenia purpura (IM administration only); intrathecal administration; live or live, attenuated virus vaccines (with immunosuppressive doses of corticosteroids).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Herpes simplex of the eye (except for short-term or emergency therapy); vaccinia and varicella (except for short-term or emergency therapy)</p></div>
<div class="block war drugH1Div" id="F8116244"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections.</p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid reactions: Rare cases of anaphylactoid reactions have been observed in patients receiving corticosteroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermal changes: Avoid injection or leakage into the dermis; dermal and/or subdermal skin depression may occur at the site of injection. Avoid deltoid muscle injection; subcutaneous atrophy may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to killed or inactivated vaccines. Exposure to chickenpox or measles should be avoided. Corticosteroids should not be used for cerebral malaria, fungal infections, or viral hepatitis. Close observation is required in patients with tuberculosis (TB) infection (latent TB) and/or TB reactivity; restrict use in TB disease (active TB) (only fulminating or disseminated TB in conjunction with antituberculosis treatment). Latent or active amebiasis should be ruled out in any patient with recent travel to tropical climates or unexplained diarrhea prior to corticosteroid initiation. Use with extreme caution in patients with <i>Strongyloides</i> infections; hyperinfection, dissemination and fatalities have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including euphoria, insomnia, mood swings, personality changes, severe depression, or psychotic manifestations. Symptoms usually occur within a few days or weeks of initiation of treatment and usually resolve with dose reduction or discontinuation; monitor for signs and symptoms of behavioral or mood changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with HF and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use corticosteroids with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk; risk may be increased with concurrent use of nonsteroidal anti-inflammatory drugs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; fluid retention may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg, within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Oral steroid treatment is not recommended for the treatment of acute optic neuritis; may increase frequency of new episodes and does not affect short- or long-term visual outcomes. Use with caution in patients with ocular herpes simplex; corneal perforation may occur; do not use in active ocular herpes simplex. Consider routine eye exams in chronic users.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma: Pheochromocytoma crisis has been reported with corticosteroids (may be fatal). Consider the risk of pheochromocytoma crisis prior to administering corticosteroids in patients with suspected pheochromocytoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Septic shock or sepsis syndrome: Corticosteroids should not be administered for the treatment of sepsis in the absence of shock (SCCM/ESICM [Annane 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic sclerosis: Use with caution in patients with systemic sclerosis; an increase in scleroderma kidney crisis incidence has been observed with corticosteroid use. Monitor BP and kidney function in patients with systemic sclerosis treated with corticosteroids (EULAR [Kowal-Bielecka 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in patients with hyperthyroidism and decreases in patients with hypothyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution in the older adult with the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Diluent for injection may contain benzyl alcohol and some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Capsule: Sprinkles are therapeutically equivalent to tablets; however, compounding tablets into a suspension, or crushing or splitting tablets could lead to a relative difference in exposure on the same nominal dose leading to symptoms of adrenal insufficiency. Dosage adjustments of oral sprinkles may be needed if adrenal insufficiency occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stress: Patients may require higher doses when subject to stress (ie, trauma, surgery, severe infection).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878741"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard 2007). In premature neonates, reports of gastrointestinal perforation in the hydrocortisone treatment arm have resulted in the closure of two large bronchopulmonary dysplasia (BPD) clinical trials (Peltoniemi 2005; Watterberg 2004); concomitant use with indomethacin or ibuprofen may increase the risk and should be avoided in this population (Seri 2006). Increased IOP may occur especially with prolonged use; in children, increased IOP has been shown to be dose dependent and produce a greater IOP in children &lt;6 years than older children treated with ophthalmic dexamethasone (Lam 2005). Hypertrophic cardiomyopathy has been reported in premature neonates.</p>
<p style="text-indent:0em;margin-top:2em;">In premature neonates, the use of high-dose dexamethasone (approximately &gt;0.5 mg/kg/day) for the prevention or treatment of BPD has been associated with adverse neurodevelopmental outcomes, including higher rates of cerebral palsy without additional clinical benefit over lower doses; current data does not support use of high doses. Data specific to hydrocortisone use in this population has shown that use &lt;7 days of therapy does not appear to be associated with adverse neurodevelopmental outcomes (Needelman 2010). Early initiation (ie, PNA &lt;24 hours) of low-dose hydrocortisone for BPD prevention was shown to improve survival without BPD in neonates born at GA &lt;28 weeks and was not associated with a statistically significant difference in neurodevelopment at 2 years corrected age compared to placebo; a secondary analysis looking at neurodevelopment according to gestation showed a statistically significant improvement in neurodevelopmental outcomes in neonates at 24 to 25 weeks gestation receiving hydrocortisone; the incidence of moderate to severe neurodevelopmental impairment was 2% in this group compared to 18% in the placebo group; no differences in neurodevelopmental outcomes were seen in neonates at 26 to 27 weeks gestation (Baud 2016; Baud 2017; Baud 2019a). Similar to early initiation, when hydrocortisone was initiated later (ie, PNA 14 to 28 days) in neonates born at &lt;30 weeks gestation, no adverse neurodevelopmental effects were seen at 2 years corrected age compared to placebo (Watterberg 2022).</p></div>
<div class="block foc drugH1Div" id="F8116380"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Sprinkle, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alkindi Sprinkle: 0.5 mg, 1 mg, 2 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Solu-CORTEF: 100 mg (1 ea); 250 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cortef: 5 mg, 10 mg, 20 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 20 mg</p></div>
<div class="block geq drugH1Div" id="F8116180"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8116382"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, sprinkles</b> (Alkindi Sprinkle Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $10.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $21.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $42.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $105.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Solu-CORTEF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $24.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $45.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $90.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $181.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cortef Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $3.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Hydrocortisone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.34 - $1.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.57 - $2.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $1.09 - $3.26</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869191"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Solu-CORTEF: 100 mg (1 ea); 250 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as base: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cortef: 10 mg, 20 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg</p></div>
<div class="block exp drugH1Div" id="F11585944"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>2 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">A 2 mg/mL oral suspension may be made with 10 mg tablets and a 1:1 mixture of Ora-Sweet and Ora-Plus. Crush ten 10 mg hydrocortisone tablets in a mortar and reduce to a fine powder. Add a small amount of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 50 mL; transfer to a calibrated amber bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 50 mL. Label “shake well.” Stable under refrigeration or at room temperature for 90 days.</p>
<div class="reference">Chong G, Decarie D, Ensom MHH. Stability of hydrocortisone in extemporaneously compounded suspension. <i>J Inform Pharmacother.</i> 2003;13:100-110.</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>2.5 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 2.5 mg/mL oral suspension may be made with either tablets or powder and a vehicle containing sodium carboxymethylcellulose (1 g), syrup BP (10 mL), hydroxybenzoate 0.1% preservatives (0.1 g), polysorbate 80 (0.5 mL), citric acid (0.6 g), and water. To make the vehicle, dissolve the hydroxybenzoate, citric acid, and syrup BP in hot water. Cool solution and add the carboxymethylcellulose; leave overnight. Crush twelve-and-one-half 20 mg hydrocortisone tablets (or use 250 mg of powder) in a mortar and reduce to a fine powder while adding polysorbate 80. Add small portions of vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 100 mL. Label “shake well” and “refrigerate.” Stable for 90 days.</p>
<div class="reference">Fawcett JP, Boulton DW, Jiang R, et al. Stability of hydrocortisone oral Suspensions prepared from tablets and powder. <i>Ann Pharmacother.</i> 1995;29(10):987-990.<span class="pubmed-id">8845559</span></div>
</div>
<div class="block adip drugH1Div" id="F53570028"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Cortef oral suspension was reformulated in July 1998; the suspending agent was changed from tragacanth to xanthan gum; this suspension was found <b>not</b> to be bioequivalent to hydrocortisone tablets in the treatment of children with congenital adrenal hyperplasia; children required higher doses of the suspension (19.6 mg/m<sup>2</sup>/day) compared to the tablets (15.2 mg/m<sup>2</sup>/day); based on these findings, Cortef suspension was voluntarily recalled from the market on July 18, 2000 (Merke 2001).</p></div>
<div class="block admp drugH1Div" id="F52614359"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with food or milk to decrease GI upset; for physiologic replacement in pediatric patients, higher doses are typically administered in the morning and midday with lower doses in the evening to replicate diurnal variation; early evening doses (18:00) may be necessary in some children (doses too close to bedtime can interfere with sleep) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25561746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25561746'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Sprinkles (Alkindi): Do not swallow capsule whole. Hold capsule so numeric strength section of the capsule is at the top and tap capsule to ensure all granules in lower section, then open the capsule by squeezing the bottom section and twisting the top off. Granules may be administered by any of the following methods: Pouring granules directly onto patient's tongue; pouring granules onto a spoon and placing in patient's mouth; or sprinkling granules onto a spoon containing a soft food (eg, yogurt, fruit puree) that is cold or at room temperature and then having patient consume preferably within 5 minutes to avoid bitter taste. Avoid getting capsule wet (if capsule is wet, granules may stick and not get delivered in dose). Do not crush or chew granules. Ingest fluids (eg, water, milk, breast milk, infant formula) after dose is administered to ensure all granules swallowed. Do not add granules directly to a liquid; may result in reduced dose delivered as well as a bitter taste. Do not administer through NG or gastric tubes; granules will clog tube.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Hydrocortisone sodium succinate may be administered by IM or IV routes. Dermal and/or subdermal skin depression may occur at the site of injection.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Avoid injection into deltoid muscle (high incidence of SubQ atrophy).</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus: Administer undiluted over at least 30 seconds; for large doses (≥500 mg), administer over 10 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Further dilute in a compatible fluid and administer over 20 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6966050']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6966050'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F8116346"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food or milk to decrease GI upset.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral:</b> For IM or IV administration: Dermal and/or subdermal skin depression may occur at injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Avoid injection into deltoid muscle (high incidence of subcutaneous atrophy).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV bolus:</b> Administer undiluted over at least 30 seconds; for large doses (≥500 mg), administer over 10 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV intermittent infusion:</b> Further dilute in a compatible fluid and administer over 20 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ</b> (off-label route): Divide injections &gt;1 mL (&gt;50 mg) into 2 or more separate injections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23672956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23672956'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F8116278"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Store in original container to protect from light. Use within 60 days of opening bottle.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vials at 20°C to 25°C (68°F to 77°F); protect from light. Heat sensitive; do not autoclave vial. Reconstituted solutions are stable for 3 days at 20°C to 25°C (68°F to 77°F); protect from light. Solutions prepared for IV infusion are stable for at least 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block meg drugH1Div" id="F56619037"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Alkindi Sprinkle: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F213876s001lbl.pdf%23page%3D14&amp;token=%2F%2FlYGzkjbdA6qugV1v1mzK2WSTzYvIv6G2HI0kEClTZAmdSMssumQqWLy78IYO3zswX1Z2SlD%2BcDPuqqsPOHjgi%2BKJeWtJNVb2LQVnzVGZo%2BAkZjABmms5kPULYdJue%2B&amp;TOPIC_ID=16001" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213876s001lbl.pdf#page=14</a></p></div>
<div class="block usep drugH1Div" id="F53570560"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases, including those of allergic, hematologic, dermatologic, gastrointestinal, ophthalmic, neoplastic, rheumatic, autoimmune, nervous system, renal, and respiratory origin (FDA approved in pediatric patients [age not specified] and adults); treatment of primary or secondary adrenocorticoid deficiency (drug of choice) (FDA approved in pediatric patients [age not specified] and adults); has also been used for management of septic shock and in neonates for treatment of hypotension and prevention of bronchopulmonary dysplasia.</p></div>
<div class="block mst drugH1Div" id="F8116164"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Hydrocortisone may be confused with hydrocodone, hydroxychloroquine, hydroCHLOROthiazide</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cortef may be confused with Coreg, Lortab</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">HCT (occasional abbreviation for hydrocortisone) is an error-prone abbreviation (mistaken as hydroCHLOROthiazide)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Solu-CORTEF may be confused with SOLU-Medrol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8116271"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8116272"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Abrocitinib.  Management: The use of abrocitinib in combination with other immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: Corticosteroids (Systemic) may diminish the therapeutic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of systemic corticosteroid is reduced. Corticosteroids (Systemic) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Baricitinib.  Management: The use of baricitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Corticosteroids (Systemic) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Corticosteroids (Systemic) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CAR-T Cell Immunotherapy: Corticosteroids (Systemic) may enhance the adverse/toxic effect of CAR-T Cell Immunotherapy. Specifically, the severity and duration of neurologic toxicities may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of CAR-T Cell Immunotherapy.  Management: Avoid use of corticosteroids as premedication before treatment with CAR-T cell immunotherapy agents. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Corticosteroids (Systemic) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing systemic corticosteroids (dosed at 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks) several weeks prior to coccidioides immitis skin antigen testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticorelin: Corticosteroids (Systemic) may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Hydrocortisone (Systemic) may diminish the diagnostic effect of Cosyntropin.  Management: Patients receiving hydrocortisone should omit their pre-test dose on the day selected for cosyntropin testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters)<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Hydrocortisone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Hydrocortisone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Hydrocortisone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and systemic corticosteroids. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: The use of deucravacitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May increase the serum concentration of Hydrocortisone (Systemic). Estrogen Derivatives may decrease the serum concentration of Hydrocortisone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Etrasimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Filgotinib.  Management: Coadministration of filgotinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 Dotatate: Corticosteroids (Systemic) may diminish the diagnostic effect of Gallium Ga 68 Dotatate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Corticosteroids (Systemic) may diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Corticosteroids (Systemic) may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Corticosteroids (Systemic) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).  Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lutetium Lu 177 Dotatate: Corticosteroids (Systemic) may diminish the therapeutic effect of Lutetium Lu 177 Dotatate.  Management: Avoid repeated use of high-doses of corticosteroids during treatment with lutetium Lu 177 dotatate. Use of corticosteroids is still permitted for the treatment of neuroendocrine hormonal crisis. The effects of lower corticosteroid doses is unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Corticosteroids (Systemic) may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (eg, for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Hydrocortisone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Corticosteroids (Systemic). Specifically, the risk of gastrointestinal bleeding, ulceration, and perforation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ozanimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Corticosteroids (Systemic) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Corticosteroids (Systemic) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Corticosteroids (Systemic) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing immunosuppressants, such as systemic corticosteroids, prior to initiating sipuleucel-T therapy. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone given for 2 or more weeks are immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Corticosteroids (Systemic) may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Corticosteroids (Systemic) may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Corticosteroids (Systemic) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Upadacitinib.  Management: Coadministration of upadacitinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone &gt; 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines 4 weeks prior to therapy if possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Corticosteroids (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F8116345"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B<sub>6</sub>, C, D, folate, calcium, zinc, phosphorus, and decreased sodium. Some products may contain sodium. </p></div>
<div class="block pri drugH1Div" id="F8116219"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts or decreased birth weight; however, information is conflicting and may be influenced by maternal dose/indication for use (Lunghi 2010; Park-Wyllie 2000; Pradat 2003). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>
<p style="text-indent:0em;margin-top:2em;">When treating patients with adrenal insufficiency (primary or central or congenital adrenal hyperplasia) during pregnancy, hydrocortisone is the preferred corticosteroid. Doses may need to be adjusted as pregnancy progresses. Pregnant patients with adrenal insufficiency should be monitored at least once each trimester (ES [Bornstein 2016]; ES [Fleseriu 2016]; ES [Speiser 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">High doses of hydrocortisone (ie, stress doses) may be required to prevent adrenal crisis during labor in patients with known or suspected adrenal insufficiency (eg, Cushingoid appearance, prolonged glucocorticoid therapy) (ES [Bornstein 2016]; ES [Fleseriu 2016]; ES [Speiser 2018]; ESE [Luger 2021]). Patients who require systemic corticosteroids for management of asthma should also be given IV corticosteroids, such as hydrocortisone, during labor and for 24 hours after delivery to prevent adrenal crisis (ACOG [Dombrowski 2008]; ERS/TSANZ [Middleton 2020]). Patients using chronic low dose steroids for rheumatic disorders generally do not need a stress dose of hydrocortisone at the time of vaginal delivery; however, stress dosing may be needed in women with multiple comorbidities treated with chronic high dose steroid therapy. Stress dosing is recommended prior to cesarean delivery (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes). Maternal asthma symptoms should be monitored monthly during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; however, systemic corticosteroids should be used to control acute exacerbations or treat severe persistent asthma. Hydrocortisone may be used when parenteral administration is required (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Hydrocortisone is approved for the treatment of rheumatic disorders, however, when systemic corticosteroids are needed in pregnancy, nonfluorinated corticosteroids (eg, prednisone) are preferred (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">For dermatologic disorders in pregnant patients, systemic corticosteroids are generally not preferred for initial therapy; should be avoided during the first trimester; and used during the second or third trimester at the lowest effective dose (Leachman 2006).</p>
<p style="text-indent:0em;margin-top:2em;">In nonpregnant patients, hydrocortisone is recommended off label as an alternative corticosteroid for the management of COVID-19 (NIH 2023). In general, the treatment of COVID-19 during pregnancy is the same as in nonpregnant patients. However, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process. Hydrocortisone is also an alternative for use in pregnant patients with severe or critical COVID-19 due to limited placental transfer. Suggested treatment algorithms are available for pregnant patients with severe or critical COVID-19 requiring corticosteroids (Saad 2020; Teelucksingh 2022). The risk of severe illness from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients (ACOG 2023). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p></div>
<div class="block mopp drugH1Div" id="F53570553"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure; weight; serum glucose; electrolytes; growth in pediatric patients; presence of infection, bone mineral density; assess hypothalamic pituitary adrenal (HPA) axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test). Signs and symptoms of behavioral or mood changes; signs and symptoms of Cushing syndrome every 6 months (pediatric patients &lt;1 year of age may require monitoring every 3 to 4 months). Monitor intraocular pressure with therapy &gt;6 weeks.</p></div>
<div class="block rerp drugH1Div" id="F53570029"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Hydrocortisone (normal endogenous morning levels): 4 to 30 mcg/mL</p></div>
<div class="block pha drugH1Div" id="F8116300"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Short-acting corticosteroid with minimal sodium-retaining potential; decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability</p></div>
<div class="block phk drugH1Div" id="F8116303"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 96% ± 20% (Czock 2005); oral sprinkles: ~87%.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV: 27 ± 7 L (Czock 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: IV: 92% ± 2% (Czock 2005); oral sprinkles: ≥90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IM: 2.2 ± 1.5 hours (Hahner 2013); IV: 2 ± 0.3 hours; Oral: 1.8 ± 0.5 hours (Czock 2005); SubQ: 4.7 ± 4.7 hours (Hahner 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: IM: 66 ± 51 minutes (Hahner 2013); Oral: 1.2 ± 0.4 hours (Czock 2005); SubQ: 91 ± 34 minutes (Hahner 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (Czock 2005).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961979"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Flazole | Flebocortid | Hydrocortisone</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Hidrocortisona | Hidrocortisona drawer | Hidrocortisona Klonal | Hidrocortisona pharmavial | Hidrocortisona richet | Hidrotisona</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Efmody | Hydrocortison | Hydrocortone</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortisone mylan | Hydrocortisone Sodium | Hydrocortisone viatris | Hysone | Solu cortef</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cortaid | Cortef | Cortinex | Cotson | Eucot | Glucort | Hydrason | Hydrocortisone | Inflanil | Rapicort</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cortril | Hydrocortisone | Solu cortef</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortisone biocodex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortison | Hydrocortone</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Androcortil | Ariscorten | Benzenil | Cortisonal | Cortiston | Cortizol | Cortizon | Flebocortid | Gliocort | Hidrocortex | Hidrocortisona | Hidrosone | Solu cortef | Succinato sodico de hidrocortisona</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortison galepharm | Hydrocortone | Plenadren | Solu cortef</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Hycort | Hydrocortisone biocodex</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cortisol | Hidrocortisona</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hydrocor.sod.succi | Hydrocortisone</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Hidrocortisona | Itrocsona | Kortafgor | Limicort | Solu cortef | Sumicort | Vesacort</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Hydrocortison | Hydrocortison Vuab | Solucortef</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Acecort | Alkindi | Efmody | Ficortril | Hydrocortison | Hydrocortison acis | Hydrocortison Galen | Hydrocortison hoechst | Hydrocortison Hoechst | Hydrocutan | Hydroson | Plenadren</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Hidrocortisona | Humera</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Hidrocortif | Solucortef</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Abix | Ampikyy | Hydrocortison | Solucortef</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortisone | Micort | Sigmacortin | Solu cortef | Solucortef</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Actocortina | Hidroaltesona | Hidrocortisona lorien</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Cort S</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ampikyy | Hydro adreson | Hydrocortison | Kyypakkaus | Plenadren | Solu cortef</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortisone biocodex | Hydrocortisone Upjohn</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alkindi | Efcortelan | Efmody | Hydrocortison | Hydrocortison tab | Hydrocortisone | Hydrocortone | Plenadren | Solu cortef</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Edicot | Hidroaltesona | Hydrocortisone | Hydrocortone | Lyo Cortin | Rolak</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Hydrocortisone | Hydrocortistab | Solu cortef | Uni Corsone</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Plenadren | Solu cortef</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Hydrocortison | Solu cortef</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fartison | Genisone | Hydrocortisone | Hyson | Lexacorton | Silacort | Solu cortef</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Efcortelan soluble | Hydrocortone | Plenadren | Solu cortef</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Solu cortef</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acucort | Alcort | Biosone | Cipcorline | Cordro | Cort S | Cortiriv | Cortisum | Cortopil | Efcorlin | H.s | Hekortin | Hisone | Hycorlin | Hycort | Hycoson | Hydrocortisone | Intacorlin | Labocort | Lycortin-s | Multicort | Novacort | Pilcort H | Primacort | Roscort | Succicort | Troycort | Unicort | Wosone | Wycort</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cortidro | Cortop | Efmody | Flebocortid | Plenadren | Solu cortef</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Hydrocortisone | Hydrosone</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cholidefeat | Cortef | Cortril | Excerate | Excerate taisho toyama iyak | Hyconate s | Hydrocorti.suc.ave | Hydrocortone | Minasetyl | Saxizon | Scheroson f | Solu cortef | Succort</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cardilan | Cort S | Cortidoz | Cortisol | Cortitab | Dawacort | Galcort | H cort | Hycorum | Labohydro | Lycortin-s | Medcort | Ocortin | Primacort | S hydro | Solu cortef | Umicort</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Corosone | Corticap | Cortisolu | Cortison | Cotico | Harond | Hiden | Hiroxon | Hydro | Hyrosine | Hyroson | Hyroxon | Hysone | Hytisone | Jr hydrocortisone | Rapison | Rotisone | Solu cortef | Whycort</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Solu cortef</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortisone | Solu cortef</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Hc cort | Hisone | Hydrocortison | Hydrocortison Acetate | Hydrocortison acis | Hydrocortison rotexmedica | Hydrocortisonum sf | Hydrocortone | Solucortef | Sopolcort h</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortisone | Hydrocortisone bepb | Solu cortef</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortison | Hydrocortison Galen | Solucortef | Sopolcortholone h</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Flebocortid | Hydrocortisone roussel</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Drosodin | Extaden | Fadol | Flebocortid | Flebonadrol | Flemex | Hidrocortis gi | Hidrocortiso gi ly | Hidrocortiso.gi | Hidrocortisona | Inotid | Nositrol | Solhidrol | Sonatalis | Ticofran | Tisodank</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dhartisone | Hycort | Hydrocortisone | Solu cortef | Stricort-100</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acmecortisone | Chazmax hydrocortisone | Cortina | Darvinks hydrocortisone | Everdestiny hydrocortisone | Hydrokris | Longecut | Spansicort | Vinco hydrocortisone | Zonason hydrortisone sodium succinate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Acecort | Efmody | Hydrocortison | Hydrocortison teva | Hydrocortison tiofarma | Plenadren | Solu cortef</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Cortef euromedica | Efmody | Hidroaltesona | Hydrocortisone accord | Hydrocortisone Alissa | Hydrocortone | Hydrokortison | Hydrokortison dak orifarm | Hydrokortison orion | Hydventia | Lilinorm | Plenadren | Solu cortef | Solucortef</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Solucortef</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Hidrocortisona | Hidrocortisona succinato sodico | Novocortil | Solu cortef | Solu cortef mix o</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biocort | Corbal | Cortin | Cortis | Cortizol | Costeron H | Cylocortix | Eurocortef | Hycorlin | Hycort | Hycortil | Hydrobet | Hydrotopic | Hydrovex | Hydrozone | Hyzonate | Pharmacort | Solu cortef | Sorvilor | Verdicort | Vitasone</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cartilan | Cortisol | Cortizone | Hicartif | Hycortisone | Hydrocort | Hyzonate | Solu cortef</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alkindi | Corhydron | Cortef | Hydrocortison | Hydrocortisonum | Hydrocortisonum aceticum | Hydrocortisonum jelfa | Hydrocortisonum sf | Hydroctin | Solucortef</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">A-hydrocort | Alkindi sprinkle | Cortef | Hydrocortisone | Solu cortef</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Hidrocortisona color | Hidrocortisona generis | Hidrocortisona roussel | Hydrocortone | Rapicort | Solu cortef</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Betacorten | Hidrocortisona | Hidrocortisona dallas | Hidrocortisona eticos | Hidrocortisona fda | Hidrocortisona fusa | Hidrocortisona imedic | Hidrocortisona klonal | Hidrocortisona lasca | Hidrocortisona nortelab | Hidrocortisona northia | Hidrocortisona prosalud | Hidrocortisona richmond | Zonac</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Hydrosone | Solu-Cortef | UC-Cort | Zycort</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Flebocortid | Hidrocortizon HF | Hidrocortizon rompharm | Hydrocortisone roussel | Hydrocortisone succinat sodic | Hydrocortisone succinat sodic eipico</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Hydrocortison | Solo cortef novamedica | Solu cortef</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ikotref | Solu cortef</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alkindi | Efmody | Hydrokortison ebb | Hydrokortison nycomed | Hydrokortison Orifarm | Hydrokortison orion | Plenadren | Solu cortef</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortisone | Solu cortef</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Hidrokortizon Altamedics | Hydrocortison | Hydrocortison hoechst | Hydrocortone | Solu cortef</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Hydrocortison | Hydrocortison Vuab | Hydrocortisone medopharm | Solucortef</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Hycortin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Hydasone | Hydracort | Hydro-adreson aquosum | Hysone</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cortef | Hydrocortisone | Hydrocortisone Medis | Hydrocortisone panpharma | Suranil</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Genkort | Hidrozon | Hydrocortison</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Efcortelan | Hydrocortisone | Hydrocortisone cyh | Saxizon | Solu cortef</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Hydrocortisone rompharm | Solucortef</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Hycort | Hydrocort | Hydrosone | Primacort | Succicort | Umicort</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Coripen | Fridalit | Hidrocortisona</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Corticina | Cortivid | Cyclocortid | Hidrocort | Hidrocortisona | Histasona | Silian | Solucortef | Wellsona</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cortaject | Covocort | Solu cortef</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cipcorlin | Dawacort | Hycorcin | Lycortin-s | Primacort | Solu cortef</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Primacort | Solu cortef</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12186608">
<a name="12186608"></a>Abraham E, Evans T. Corticosteroids and septic shock [editorial]. <i>JAMA</i>. 2002;288(7):886-887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12186608/pubmed" id="12186608" target="_blank">12186608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADSHG.2017">
<a name="ADSHG.2017"></a>Addison’s Clinical Advisory Panel. Surgical guidelines for Addison’s disease and other forms of adrenal insufficiency. Addison’s Disease Self-Help Group (ADSHG) website. http://www.addisons.org.uk/surgery. Published 2017. Accessed June 19, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21867553">
<a name="21867553"></a>Ahmet A, Kim H, and Spier S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. <i>Allergy Asthma Clin Immunol</i>. 2011;7:13. doi:10.1186/1710-1492-7-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/21867553/pubmed" id="21867553" target="_blank">21867553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-A-Hydrocort.1">
<a name="A-Hydrocort.1"></a>A-Hydrocort (hydrocortisone injection) [prescribing information]. Lake Forest, IL: Hospira; October 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alkindi.1">
<a name="Alkindi.1"></a>Alkindi Sprinkle (hydrocortisone) [prescribing information]. Deer Park, IL: Eton Pharmaceuticals Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25288693">
<a name="25288693"></a>Allolio B. Extensive expertise in endocrinology. Adrenal crisis. <i>Eur J Endocrinol</i>. 2015;172(3):R115-R124. doi:10.1530/EJE-14-0824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/25288693/pubmed" id="25288693" target="_blank">25288693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11099616">
<a name="11099616"></a>American Academy of Pediatrics (AAP). Technical report: congenital adrenal hyperplasia. Section on Endocrinology and Committee on Genetics. <i>Pediatrics</i>. 2000;106(6):1511-1518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11099616/pubmed" id="11099616" target="_blank">11099616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Statement of endorsement: congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. <i>Pediatrics</i>. 2010;126(5):1051. http://pediatrics.aappublications.org/cgi/content/extract/126/5/1051. Accessed May 10, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetricians-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed April 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology. ACR manual on contrast media: ACR Committee on Drugs and Contrast Media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Updated January 2021. Accessed February 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32876697">
<a name="32876697"></a>Angus DC, Derde L, Al-Beidh F, et al; Writing Committee for the REMAP-CAP Investigators. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. <i>JAMA</i>. Published online September 2, 2020. doi:10.1001/jama.2020.17022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/32876697/pubmed" id="32876697" target="_blank">32876697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28938253">
<a name="28938253"></a>Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. <i>Crit Care Med</i>. 2017;45(12):2078-2088. doi:10.1097/CCM.0000000000002737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/28938253/pubmed" id="28938253" target="_blank">28938253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29490185">
<a name="29490185"></a>Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock.<i> N Engl J Med.</i> 2018;378(9):809-818. doi:10.1056/NEJMoa1705716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/29490185/pubmed" id="29490185" target="_blank">29490185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12186604">
<a name="12186604"></a>Annane D, Sebille V, Charpentier C, et al. Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock. <i>JAMA</i>. 2002;288(7):862-871.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12186604/pubmed" id="12186604" target="_blank">12186604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12788587">
<a name="12788587"></a>Arlt W, Allolio B. Adrenal Insufficiency. <i>Lancet</i>. 2003;361(9372):1881-1893.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12788587/pubmed" id="12788587" target="_blank">12788587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25733761">
<a name="25733761"></a>Auron M, Raissouni N. Adrenal insufficiency. <i>Pediatr Rev</i>. 2015;36(3):92-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/25733761/pubmed" id="25733761" target="_blank">25733761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.1">
<a name="expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26916176">
<a name="26916176"></a>Baud O, Maury L, Lebail F, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. <i>Lancet</i>. 2016;387(10030):1827-1836. doi:10.1016/S0140-6736(16)00202-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/26916176/pubmed" id="26916176" target="_blank">26916176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28384828">
<a name="28384828"></a>Baud O, Trousson C, Biran V, et al. Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. <i>JAMA</i>. 2017;317(13):1329-1337. doi:10.1001/jama.2017.2692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/28384828/pubmed" id="28384828" target="_blank">28384828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29321180">
<a name="29321180"></a>Baud O, Trousson C, Biran V, et al. Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2019a;104(1):F30-F35. doi:10.1136/archdischild-2017-313756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/29321180/pubmed" id="29321180" target="_blank">29321180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31043325">
<a name="31043325"></a>Baud O, Watterberg KL. Prophylactic postnatal corticosteroids: Early hydrocortisone. <i>Semin Fetal Neonatal Med</i>. 2019b;24(3):202-206. doi:10.1016/j.siny.2019.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/31043325/pubmed" id="31043325" target="_blank">31043325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1734247">
<a name="1734247"></a>Beck RW, Cleary PA, Anderson MM Jr, et al. A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. The Optic Neuritis Study Group. <i>N Engl J Med</i>. 1992;326(9):581-588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/1734247/pubmed" id="1734247" target="_blank">1734247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9559600">
<a name="9559600"></a>Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. <i>Crit Care Med</i>. 1998;26(4):645-650. doi:10.1097/00003246-199804000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/9559600/pubmed" id="9559600" target="_blank">9559600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi:10.1210/jc.2015-1710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32424397">
<a name="32424397"></a>Bothou C, Anand G, Li D, et al. Current management and outcome of pregnancies in women with adrenal insufficiency: experience from a multicenter survey. <i>J Clin Endocrinol Metab</i>. 2020;105(8):e2853-e2863. doi:10.1210/clinem/dgaa266<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/32424397/pubmed" id="32424397" target="_blank">32424397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17511554">
<a name="17511554"></a>Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the Management of Severe Traumatic Brain Injury. XV. Steroids. <i>J Neurotrauma</i>. 2007;24(suppl 1):91-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17511554/pubmed" id="17511554" target="_blank">17511554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19325359">
<a name="19325359"></a>Brierley J, Carcillo JA, Choong K, et al. Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2009;37(2):666-688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/19325359/pubmed" id="19325359" target="_blank">19325359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cameron.1">
<a name="Cameron.1"></a>Cameron P, Jelinek G, Everitt I, Browne G, Raftos J, eds. <i>Textbook of Paediatric Emergency Medicine</i>. Toronto: Elsevier; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12072696">
<a name="12072696"></a>Carcillo JA, Fields AI. Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Patients in Septic Shock. <i>Crit Care Med</i>. 2002;30(6):1365-1378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12072696/pubmed" id="12072696" target="_blank">12072696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23148158">
<a name="23148158"></a>Carroll R, Matfin G. Endocrine and metabolic emergencies: thyroid storm. <i>Ther Adv Endocrinol Metab</i>. 2010;1(3):139-145. doi:10.1177/2042018810382481<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/23148158/pubmed" id="23148158" target="_blank">23148158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594318">
<a name="12594318"></a>Cooper MS, Stewart PM. Corticosteroid Insufficiency in Acutely Ill Patients. <i>N Engl J Med</i>. 2003;348(8):727-734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12594318/pubmed" id="12594318" target="_blank">12594318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cortef.1">
<a name="Cortef.1"></a>Cortef (hydrocortisone tablets) [prescribing information]. New York, NY: Pfizer; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cortef.2">
<a name="Cortef.2"></a>Cortef (hydrocortisone tablets) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11779267">
<a name="11779267"></a>Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. <i>JAMA</i>. 2002;287(2):236-240. doi:10.1001/jama.287.2.236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11779267/pubmed" id="11779267" target="_blank">11779267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12078323">
<a name="12078323"></a>Cowett RM, Loughead JL. Neonatal Glucose Metabolism: Differential Diagnoses, Evaluation, and Treatment of Hypoglycemia. <i>Neonatal Netw</i>. 2002;21(4):9-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12078323/pubmed" id="12078323" target="_blank">12078323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cummings.2022">
<a name="Cummings.2022"></a>Cummings JJ, Pramanik AK; Committee on Fetus and Newborn. Postnatal corticosteroids to prevent or treat chronic lung disease following preterm birth. <i>Pediatrics</i>. 2022;149(6):e2022057530.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15634032">
<a name="15634032"></a>Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clin Pharmacokinet</i>. 2005;44(1):61-98. doi:10.2165/00003088-200544010-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/15634032/pubmed" id="15634032" target="_blank">15634032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28509730">
<a name="28509730"></a>Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093. doi:10.1097/CCM.0000000000002425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/28509730/pubmed" id="28509730" target="_blank">28509730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12472328">
<a name="12472328"></a>de Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study. <i>JAMA</i>. 2002;288(22):2859-2867.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12472328/pubmed" id="12472328" target="_blank">12472328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353941">
<a name="23353941"></a>Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637. doi:10.1097/CCM.0b013e31827e83af<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/23353941/pubmed" id="23353941" target="_blank">23353941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32876689">
<a name="32876689"></a>Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. <i>JAMA</i>. Published online September 2, 2020. doi:10.1001/jama.2020.16761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/32876689/pubmed" id="32876689" target="_blank">32876689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18238988">
<a name="18238988"></a>Dombrowski MP, Schatz M; ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. <i>Obstet Gynecol</i>. 2008;111(2, pt 1):457-464. doi:10.1097/AOG.0b013e3181665ff4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18238988/pubmed" id="18238988" target="_blank">18238988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32808988">
<a name="32808988"></a>Dulek DE, Fuhlbrigge RC, Tribble AC, et al. Multidisciplinary guidance regarding the use of immunomodulatory therapies for acute COVID-19 in pediatric patients. <i>J Pediatric Infect Dis Soc</i>. Published online August 18, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/32808988/pubmed" id="32808988" target="_blank">32808988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15936423">
<a name="15936423"></a>Edwards P, Arango M, Balica L, et al. Final Results of MRC Crash, A Randomized Placebo-Controlled Trial of Intravenous Corticosteroid in Adults With Head Injury - Outcomes at 6 Months. <i>Lancet</i>. 2005;365(9475):1957-1959.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/15936423/pubmed" id="15936423" target="_blank">15936423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25561746">
<a name="25561746"></a>Elder CJ, Dimitri P. <i>Arch Dis Child Educ Pract Ed</i>. 2015;100(5):272-276. doi:10.1136/archdischild-2014-307325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/25561746/pubmed" id="25561746" target="_blank">25561746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021.<i> Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31945371">
<a name="31945371"></a>Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. <i>Gastroenterology</i>. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/31945371/pubmed" id="31945371" target="_blank">31945371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736313">
<a name="27736313"></a>Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/27736313/pubmed" id="27736313" target="_blank">27736313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gardner.1">
<a name="Gardner.1"></a>Gardner DG, Chapter 24. Endocrine Emergencies, Greenspan’s Basic &amp; Clinical Endocrinology, 9ed. 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2">
<a name="GINA.2"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27483065">
<a name="27483065"></a>Gordon AC, Mason AJ, Thirunavukkarasu N, et al; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. <i>JAMA</i>. 2016;316(5):509-518. doi:10.1001/jama.2016.10485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/27483065/pubmed" id="27483065" target="_blank">27483065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19023528">
<a name="19023528"></a>Gupta P and Bhatia V. Corticosteroid physiology and principles of therapy.<i> Indian J Pediatr</i>. 2008;75(10):1039-1044. doi:10.1007/s12098-008-0208-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/19023528/pubmed" id="19023528" target="_blank">19023528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23672956">
<a name="23672956"></a>Hahner S, Burger-Stritt S, Allolio B. Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. <i>Eur J Endocrinol</i>. 2013;169(2):147-154. doi:10.1530/EJE-12-1057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/23672956/pubmed" id="23672956" target="_blank">23672956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9475694">
<a name="9475694"></a>Halamek LP, Stevenson DK. Neonatal Hypoglycemia, Part II: Pathophysiology and Therapy. <i>Clin Pediatr (Phila)</i>. 1998;37(1):11-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/9475694/pubmed" id="9475694" target="_blank">9475694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34313697">
<a name="34313697"></a>Halbmeijer NM, Onland W, Cools F, et al. Effect of systemic hydrocortisone initiated 7 to 14 days after birth in ventilated preterm infants on mortality and neurodevelopment at 2 years' corrected age: follow-up of a randomized clinical trial. <i>JAMA</i>. 2021;326(4):355-357. doi:10.1001/jama.2021.9380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/34313697/pubmed" id="34313697" target="_blank">34313697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hamrahian.1">
<a name="Hamrahian.1"></a>Hamrahian AH. The management of the surgical patient taking glucocorticoids. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 22, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14523168">
<a name="14523168"></a>Han YY, Carcillo JA, Dragotta MA, et al. Early Reversal of Pediatric-Neonatal Septic Shock by Community Physicians is Associated With Improved Outcome. <i>Pediatrics</i>. 2003;112(4):793-799.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/14523168/pubmed" id="14523168" target="_blank">14523168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245435">
<a name="18245435"></a>Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18245435/pubmed" id="18245435" target="_blank">18245435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19693023">
<a name="19693023"></a>Higgins S, Friedlich P, Seri I. Hydrocortisone for Hypotension and Vasopressor Dependence in Preterm Neonates: A Meta-Analysis. <i>J Perinatol</i>. 2010;30(6):373-378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/19693023/pubmed" id="19693023" target="_blank">19693023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12519925">
<a name="12519925"></a>Hotchkiss RS, Karl IE. The Pathophysiology and Treatment of Sepsis. <i>N Engl J Med</i>. 2003;348(2):138-150.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12519925/pubmed" id="12519925" target="_blank">12519925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24330030">
<a name="24330030"></a>Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. <i>J Intern Med</i>. 2014;275(2):104-115. doi:10.1111/joim.12162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/24330030/pubmed" id="24330030" target="_blank">24330030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hydrocortisone.1">
<a name="Hydrocortisone.1"></a>Hydrocortisone tablets [prescribing information]. Columbus, OH: American Health Packaging; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18245938">
<a name="18245938"></a>Jain A, Aggarwal R, Jeevasanker M, et al. Hypoglycemia in the Newborn. <i>Indian J Pediatr</i>, 2008;75(1):63-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18245938/pubmed" id="18245938" target="_blank">18245938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25266247">
<a name="25266247"></a>Jonklaas J, Bianco AC, Bauer AJ, et al; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. <i>Thyroid</i>. 2014;24(12):1670-1751. doi:10.1089/thy.2014.0028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/25266247/pubmed" id="25266247" target="_blank">25266247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12426230">
<a name="12426230"></a>Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. <i>Am J Respir Crit Care Med.</i> 2003;167(4):512-20. doi: 10.1164/rccm.200205-446OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/12426230/pubmed" id="12426230" target="_blank">12426230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932528">
<a name="15932528"></a>Lam DS, Fan DS, Ng JS, et al. Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial. <i>Clin Experiment Ophthalmol</i>. 2005;33(3):252-258.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/15932528/pubmed" id="15932528" target="_blank">15932528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8368224">
<a name="8368224"></a>LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. <i>Am J Med</i>. 1993;95(3):258-264. doi:10.1016/0002-9343(93)90277-v<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/8368224/pubmed" id="8368224" target="_blank">8368224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-vi. doi:10.1016/j.det.2006.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23153216">
<a name="23153216"></a>Lebbe M, Arlt W. What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? <i>Clin Endocrinol (Oxf)</i>. 2013;78(4):497-502. doi:10.1111/cen.12097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/23153216/pubmed" id="23153216" target="_blank">23153216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17332238">
<a name="17332238"></a>Leonard MB. Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease. <i>Pediatrics</i>. 2007;119(suppl 2):S166-S174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17332238/pubmed" id="17332238" target="_blank">17332238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34425558">
<a name="34425558"></a>Luger A, Broersen LHA, Biermasz NR, et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. <i>Eur J Endocrinol</i>. 2021;185(3):G1-G33. doi:10.1530/EJE-21-0462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/34425558/pubmed" id="34425558" target="_blank">34425558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20977425">
<a name="20977425"></a>Lunghi L, Pavan B, Biondi C, et al. Use of Glucocorticoids in Pregnancy.<i> Curr Pharm Des</i>. 2010;16(32):3616-3637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/20977425/pubmed" id="20977425" target="_blank">20977425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17576782">
<a name="17576782"></a>Maguire AM, Ambler GR, Moore B, et al. Prolonged hypocortisolemia in hydrocortisone replacement regimens in adrenocorticotrophic hormone deficiency. <i>Pediatrics</i>. 2007;120(1):e164-e171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17576782/pubmed" id="17576782" target="_blank">17576782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21985166">
<a name="21985166"></a>Makol A, Wright K, Amin S. Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management. <i>Drugs</i>. 2011;71(15):1973-1987.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/21985166/pubmed" id="21985166" target="_blank">21985166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29264549">
<a name="29264549"></a>Mallappa A, Nella AA, Kumar P, et al. Alterations in hydrocortisone pharmacokinetics in a patient with congenital adrenal hyperplasia following bariatric surgery.<i> J Endocr Soc</i>. 2017;1(7):994-1001. doi:10.1210/js.2017-00215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/29264549/pubmed" id="29264549" target="_blank">29264549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18496365">
<a name="18496365"></a>Marik PE, Pastores SM, Annane D, et al. Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2008;36(6):1937-1949.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18496365/pubmed" id="18496365" target="_blank">18496365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Marx.1">
<a name="Marx.1"></a>Marx, JA, ed. <i>Rosen's Emergency Medicine: Concepts and Clinical Practice</i>. 8th ed. Elsevier, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18504331">
<a name="18504331"></a>McGee S, Hirschmann J. Use of Corticosteroids in Treating Infectious Diseases. <i>Arch Intern Med</i>. 2008;168(10):1034-1046.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18504331/pubmed" id="18504331" target="_blank">18504331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24060796">
<a name="24060796"></a>Menon, K. Use of hydrocortisone for refractory shock in children. <i>Crit Care Med</i>. 2013;41(10):e294-295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/24060796/pubmed" id="24060796" target="_blank">24060796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11232038">
<a name="11232038"></a>Merke DP, Cho D, Calis KA, et al. Hydrocortisone Suspension and Hydrocortisone Tablets are not Bioequivalent in the Treatment of Children With Congenital Adrenal Hyperplasia. <i>J Clin Endocrinol Metab</i>. 2001;86(1):441-445.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11232038/pubmed" id="11232038" target="_blank">11232038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6966050">
<a name="6966050"></a>Miller JJ 3rd. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. <i>Pediatrics</i>. 1980;65(5):989-994.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/6966050/pubmed" id="6966050" target="_blank">6966050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11967038">
<a name="11967038"></a>N'Gankam V, Uehlinger D, Dick B, Frey BM, Frey FJ. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. <i>Kidney Int</i>. 2002;61(5):1859-1866. doi:10.1046/j.1523-1755.2002.00308.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11967038/pubmed" id="11967038" target="_blank">11967038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27012010">
<a name="27012010"></a>Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/27012010/pubmed" id="27012010" target="_blank">27012010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2021">
<a name="NIH.2021"></a>National Institutes of Health (NIH). COVID-19 treatment guidelines: therapeutic management of patients with COVID-19. <a href="https://www.covid19treatmentguidelines.nih.gov/therapeutic-management" target="_blank">https://www.covid19treatmentguidelines.nih.gov/therapeutic-management</a>. Updated September 26, 2022. Accessed September 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2">
<a name="NIH.2"></a>National Institutes of Health (NIH). COVID-19 treatment guidelines: therapeutic management of patients with COVID-19. <a href="https://www.covid19treatmentguidelines.nih.gov/therapeutic-management" target="_blank">https://www.covid19treatmentguidelines.nih.gov/therapeutic-management</a>. Updated April 20, 2023. Accessed May 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20139411">
<a name="20139411"></a>Needelman H, Hoskoppal A, Roberts H, et al. The Effect of Hydrocortisone on Neurodevelopmental Outcome in Premature Infants Less Than 29 Weeks' Gestation. <i>J Child Neurol</i>. 2010;25(4):448-452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/20139411/pubmed" id="20139411" target="_blank">20139411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16452355">
<a name="16452355"></a>Ng PC, Lee CH, Bnur FL, et al. A Double-Blind, Randomized, Controlled Study of a 'Stress Dose' of Hydrocortisone for Rescue Treatment of Refractory Hypotension in Preterm Infants. <i>Pediatrics</i>. 2006;117(2):367-375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/16452355/pubmed" id="16452355" target="_blank">16452355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10023279">
<a name="10023279"></a>Nicholson G, Burrin JM, Hall GM. Peri-operative steroid supplementation. <i>Anaesthesia</i>. 1998;53(11):1091-1104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/10023279/pubmed" id="10023279" target="_blank">10023279</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26222757">
<a name="26222757"></a>Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831. doi:10.1210/jc.2015-1818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/26222757/pubmed" id="26222757" target="_blank">26222757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17015536">
<a name="17015536"></a>Noori S, Friedlich P, Wong P, et al. Hemodynamic Changes After Low-Dosage Hydrocortisone Administration in Vasopressor-Treated Preterm and Term Neonates. <i>Pediatrics</i>. 2006;118(4):1456-1466.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17015536/pubmed" id="17015536" target="_blank">17015536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-OConnell.1">
<a name="OConnell.1"></a>O’Connell MB, Fritsch MA. Musculoskeletal and connective tissue disorders. <i>Fundamentals of Geriatric Pharmacotherapy,</i> 2<sup>nd</sup> ed. Hutchison LC, Sleeper RB, Eds. ASHP Publications, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30694322">
<a name="30694322"></a>Onland W, Cools F, Kroon A, et al. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. <i>JAMA</i>. 2019;321(4):354-363. doi:10.1001/jama.2018.21443<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/30694322/pubmed" id="30694322" target="_blank">30694322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3998938">
<a name="3998938"></a>Ost L, Wettrell G, Björkhem I, Rane A. Prednisolone excretion in human milk. <i>J Pediatr</i>. 1985;106(6):1008-1011. doi:10.1016/s0022-3476(85)80259-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/3998938/pubmed" id="3998938" target="_blank">3998938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11091360">
<a name="11091360"></a>Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth Defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies. <i>Teratology</i>. 2000;62(6):385-392.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11091360/pubmed" id="11091360" target="_blank">11091360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28518133">
<a name="28518133"></a>Peeples ES. An evaluation of hydrocortisone dosing for neonatal refractory hypotension. <i>J Perinatol</i>. 2017;37(8):943-946. doi:10.1038/jp.2017.68<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/28518133/pubmed" id="28518133" target="_blank">28518133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15870666">
<a name="15870666"></a>Peltoniemi O, Kari MA, Heinonen K, et al. Pretreatment Cortisol Values May Predict Responses to Hydrocortisone Administration for the Prevention of Bronchopulmonary Dysplasia in High-Risk Infants. <i>J Pediatr</i>. 2005;146(5):632-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/15870666/pubmed" id="15870666" target="_blank">15870666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14745915">
<a name="14745915"></a>Pradat P, Robert-Gnansia E, Di Tanna GL, et al. First Trimester Exposure to Corticosteroids and Oral Clefts. <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(12):968-970.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/14745915/pubmed" id="14745915" target="_blank">14745915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RECOVERY.1">
<a name="RECOVERY.1"></a>Randomised Evaluation of COVID-19 Therapy (RECOVERY). Information for site staff. https://www.recoverytrial.net/for-site-staff. Updated August 12, 2020. Accessed September 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32678530">
<a name="32678530"></a>RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with covid-19 - preliminary report. <i>N Engl J Med</i>. Published online July 17, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/32678530/pubmed" id="32678530" target="_blank">32678530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15474134">
<a name="15474134"></a>Roberts I, Yates D, Sandercock P, et al. Effect of Intravenous Corticosteroids on Death Within 14 days in 10,008 Adults With Clinically Significant Head Injury (MRC CRASH trial): Randomised Placebo-Controlled Trial. <i>Lancet</i>. 2004;364(9442):1321-1328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/15474134/pubmed" id="15474134" target="_blank">15474134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi10.1089/thy.2016.0229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840605">
<a name="30840605"></a>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. <i>Am J Gastroenterol</i>. 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/30840605/pubmed" id="30840605" target="_blank">30840605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32769659">
<a name="32769659"></a>Saad AF, Chappell L, Saade GR, Pacheco LD. Corticosteroids in the management of pregnant patients with coronavirus disease (COVID-19). <i>Obstet Gynecol</i>. 2020;136(4):823-826. doi:10.1097/AOG.0000000000004103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/32769659/pubmed" id="32769659" target="_blank">32769659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8161268">
<a name="8161268"></a>Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. <i>Ann Surg</i>. 1994;219(4):416-425. doi:10.1097/00000658-199404000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/8161268/pubmed" id="8161268" target="_blank">8161268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25385533">
<a name="25385533"></a>Sarafoglou K, Gonzalez-Bolanos MT, Zimmerman CL, Boonstra T, Yaw Addo O, Brundage R. Comparison of cortisol exposures and pharmacodynamic adrenal steroid responses to hydrocortisone suspension vs. commercial tablets. <i>J Clin Pharmacol</i>. 2015;55(4):452-457. doi:10.1002/jcph.424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/25385533/pubmed" id="25385533" target="_blank">25385533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16452371">
<a name="16452371"></a>Seri I. Hydrocortisone and Vasopressor-Resistant Shock in Preterm Neonates. <i>Pediatrics</i>. 2006;117(2):516-518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/16452371/pubmed" id="16452371" target="_blank">16452371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11331688">
<a name="11331688"></a>Seri I, Tan R, Evans J. Cardiovascular Effects of Hydrocortisone in Preterm Infants With Pressor-Resistant Hypotension. <i>Pediatrics</i>. 2001;107(5):1070-1074.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/11331688/pubmed" id="11331688" target="_blank">11331688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242136">
<a name="17242136"></a>Shulman DI, Palmert MR, Kemp SF; Lawson Wilkins Drug and Therapeutics Committee. Adrenal insufficiency: still a cause of morbidity and death in childhood. <i>Pediatrics</i>. 2007;119(2):e484-e494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17242136/pubmed" id="17242136" target="_blank">17242136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solu-Cortef.3">
<a name="Solu-Cortef.3"></a>Solu-Cortef (hydrocortisone sodium) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solu-Cortef.1">
<a name="Solu-Cortef.1"></a>Solu-Cortef (hydrocortisone sodium) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solu-Cortef.2">
<a name="Solu-Cortef.2"></a>Solu-Cortef (hydrocortisone) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; May 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solu-Cortef.3">
<a name="Solu-Cortef.3"></a>Solu-Cortef preservative free (hydrocortisone sodium) [prescribing information]. New York, NY: Pfizer; received June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30272171">
<a name="30272171"></a>Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(11):4043-4088. doi:10.1210/jc.2018-01865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/30272171/pubmed" id="30272171" target="_blank">30272171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18184957">
<a name="18184957"></a>Sprung CL, Annane D, Keh D, et al. Hydrocortisone Therapy for Patients With Septic Shock. <i>N Engl J Med. </i>2008;358(2):111-124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/18184957/pubmed" id="18184957" target="_blank">18184957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32876694">
<a name="32876694"></a>Sterne JAC, Murthy S, Diaz JV, et al; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. <i>JAMA</i>. Published online September 2, 2020. doi:10.1001/jama.2020.17023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/32876694/pubmed" id="32876694" target="_blank">32876694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>“Technical Report: Congenital Adrenal Hyperplasia,” American Academy of Pediatrics, Section on Endocrinology and Committee on Genetics. <i>Pediatrics</i>. 2000;106(6):1511-1518.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36337130">
<a name="36337130"></a>Teelucksingh S, Nana M, Nelson-Piercy C. Managing COVID-19 in pregnant women. <i>Breathe (Sheff)</i>. 2022;18(2):220019. doi:10.1183/20734735.0019-2022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/36337130/pubmed" id="36337130" target="_blank">36337130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20103758">
<a name="20103758"></a>The COIITSS Study Investigators. Corticosteroid Treatment and Intensive Insulin Therapy for Septic Shock in Adults. <i>JAMA</i>. 2010;303(4):341-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/20103758/pubmed" id="20103758" target="_blank">20103758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17437510">
<a name="17437510"></a>Thomson AH, Devers MC, Wallace AM, et al. Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. <i>Clin Endocrinol (Oxf)</i>. 2007;66(6):789-796. doi:10.1111/j.1365-2265.2007.02812.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17437510/pubmed" id="17437510" target="_blank">17437510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29347874">
<a name="29347874"></a>Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. <i>N Engl J Med. </i>2018;378(9):797-808. doi:10.1056/NEJMoa1705835<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/29347874/pubmed" id="29347874" target="_blank">29347874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27156187">
<a name="27156187"></a>Watterberg KL. Hydrocortisone dosing for hypotension in newborn infants: less is more. <i>J Pediatr</i>. 2016;174:23-26.e1. doi:10.1016/j.jpeds.2016.04.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/27156187/pubmed" id="27156187" target="_blank">27156187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20819899">
<a name="20819899"></a>Watterberg KL; American Academy of Pediatrics Committee on Fetus and Newborn. Policy statement--postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. <i>Pediatrics</i>. 2010;126(4):800-808. doi:10.1542/peds.2010-1534<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/20819899/pubmed" id="20819899" target="_blank">20819899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15574629">
<a name="15574629"></a>Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of Early Adrenal Insufficiency to Prevent Bronchopulmonary Dysplasia: A Multicenter Trial. <i>Pediatrics</i>. 2004;114(6):1649-1657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/15574629/pubmed" id="15574629" target="_blank">15574629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10585975">
<a name="10585975"></a>Watterberg KL, Gerdes JS, Gifford KL, et al. Prophylaxis Against Early Adrenal Insufficiency to Prevent Chronic Lung Disease in Premature Infants. <i>Pediatrics</i>. 1999;104(6):1258-1263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/10585975/pubmed" id="10585975" target="_blank">10585975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35320643">
<a name="35320643"></a>Watterberg KL, Walsh MC, Li L, et al. Hydrocortisone to improve survival without bronchopulmonary dysplasia. <i>N Engl J Med</i>. 2022;386(12):1121-1131. doi:10.1056/NEJMoa2114897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/35320643/pubmed" id="35320643" target="_blank">35320643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17325831">
<a name="17325831"></a>Weber-Carstens S, Deja M, Bercker S, et al. Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients. <i>Intensive Care Med</i>. 2007;33(4):730-733.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydrocortisone-systemic-pediatric-drug-information/abstract-text/17325831/pubmed" id="17325831" target="_blank">17325831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2020">
<a name="WHO.2020"></a>World Health Organization (WHO). Corticosteroids for COVID-19: living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. Published September 2, 2020. Accessed December 9, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 16001 Version 472.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
